Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070629 · ClinicalTrials.gov registry record · Phase 2
CPG 7909 Injection in Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT00070629 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 116 participants.
The verdict
NCT00070629, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every other treatment cycle until disease progression.
Interventions
- DRUG Chemotherapy
- DRUG CPG 7909
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2003-05 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070629
The ClinicalTrials.gov registry entry for NCT00070629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Chemotherapy is the first listed.
NCT00070629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070629 about?
NCT00070629 is a clinical study titled "CPG 7909 Injection in Non-Small Cell Lung Cancer". Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered sub...
What is the current status of trial NCT00070629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2003-05. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00070629?
The interventions under investigation include: Chemotherapy (DRUG), CPG 7909 (DRUG).
Who is sponsoring clinical trial NCT00070629?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.